Welltok l Optimizing Health, Maximizing Rewards | Board of Directors
page-template,page-template-full_width,page-template-full_width-php,page,page-id-519,ajax_fade,page_not_loaded,,select-theme-ver-3.4,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

Our Board of Directors

We’ve assembled one of the most experienced, successful and diverse boards of directors in the industry. Their deep experience ranges from healthcare IT, enterprise software and mobile development to consumer engagement and social networking technologies.
Read Bio

Jeff is the strategic and visionary leader for Welltok, developing the first holistic, agnostic Health Optimization Platform.

He is widely recognized as a healthcare IT entrepreneur and innovator based on his 30-year track record of successfully applying technologies to address the complex problems facing the healthcare industry.

Prior to Welltok, Jeff founded TriZetto, the first industry vertical SaaS enterprise solution, and originated the concept of Integrated Healthcare Management. During his tenure as Chairman and CEO, Jeff led TriZetto through a successful IPO and $1.4B private equity buyout.

Jeff currently serves as a member of the board of directors for Quality Systems, Inc. (NASDAQ:QSII) and Alignment Healthcare, as well as on boards for Hoag Hospital in Newport Beach and University of California at Irvine’s Center for Health Care Management & Policy. Jeff received his bachelor’s degree with high honors in business administration/management information systems from the University of Illinois.

Read Bio

Stephen is a partner at Bessemer and leads the firm’s healthcare investing activities.

He currently sits on the boards of Welltok, Health Essentials, DocuTAP, Ovascience (NASDAQ: OVAS), Flex Pharma, Allena Pharmaceuticals and Alcresta, and he is actively involved in BVP’s investment in Clearcare.

Steve has also been actively involved in Bessemer’s investments in Liazon, acquired by Towers Watson; Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ:AFFY); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec, Verastem (NASDAQ: VSTM), Acceleron (NASDAQ: XLRN), Proteon (NASDAQ: PRTO) and Restore Medical (NASDAQ: REST), acquired by Medtronic.

Steve was recognized by Forbes Magazine as one of the top healthcare investors in the industry.

Read Bio

Kevin’s deep knowledge of the enterprise and consumer technology sectors comes from time spent at blue chip companies, including Microsoft and Electronic Arts, and his experience as an entrepreneur.

Kevin spends a significant portion of his time working with digital health companies including Doximity, Augmedix and Welltok. He was also previously on the board of Veeva Systems. Kevin’s other investments include Handshake, VigLink and Zettics.

Read Bio

Nina Kjellson is a General Partner at Canaan Partners focused on biopharmaceuticals and digital health investments.

Previously, Nina was a General Partner at InterWest, where she managed healthcare investments for 13 years. She remains is a consultant for InterWest and represents the firm on the Welltok board.

Nina is an active board member of Eiger Biopharmaceuticals, Lycera and Ocera (NASDAQ: OCRX). She is also co-chair of ConsumerMed.org, a mentor to the BluePrint Health Accelerator, and serves on the board of the California Family Health Council.

Read Bio

Bruce Hallett is a co-founder of Miramar Venture Partners and brings his enthusiasm for innovation, product strategy and team building to Miramar’s portfolio of tech startup companies. With over two decades of collaborations with technology entrepreneurs, Bruce leads Miramar investments in mobile Internet solutions and software.

Bruce received his BA magna cum laude from UC Irvine and his JD from UCLA. From 2007-2010, he was Chair of the Chief Executive Roundtable at UC Irvine and from 2010-2012 Bruce served as UC Alumni Regent on the Board of Regents of the University of California. He is currently President of the UC Irvine Alumni Association and also serves on UC President Napolitano’s Innovation Council and is a member of the UCLA Venture Fund.

Read Bio

Mohamad heads the healthcare services and healthcare information technology investment practice for NEA.

He is currently a Director of American Pathology Partners, BetterDoctor, DaVita NephroLife, DSI Renal, Elements Behavioral Health, Nova Medical Centers, Radiology Partners, SCI Solutions, and Welltok.

He is a Board Observer of BENU, and Vantage Oncology. Mohamad’s past investments include Bravo Health, CHG Healthcare, Long Term Care Group and ppoNEXT.

Read Bio

Michael is a General Partner and Co-founder of Flare Capital Partners, an early-stage healthcare technology venture capital firm. Prior to co-founding Flare Capital Partners, Michael was the founding General Partner of Flybridge Capital Partners where he led the firm’s healthcare investments.

Some of his existing and prior board seats include Explorys, HealthVerity, Taris, T2 Biosystems and Welltok.

In addition Michael serves on several association boards including the Industry Advisory Board for the Cleveland Clinic, the Investment Committee for the Partners Innovation Fund and was on the Executive Committee of the National Venture Capital Association. Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School.

Read Bio

Ellen Koskinas is the Managing Director of Hearst Health Ventures and leads the fund’s investing efforts. Her deep knowledge of healthcare comes from her operating experience at Guidant, where she started a new business which has grown to over $200MM in revenues, and her experience at McKinsey, consulting to leading health care organizations on key strategic and operational challenges.

Ellen is a board member of Tonic Health and serves as an observer on the board of Welltok. She also served on the board of CareInSync, prior to its acquisition by Zynx Health. Previously, Ellen was a Partner at InterWest Partners, where she led the firm’s investments in five healthcare companies, including one that is now public.

Ellen has served as a frequent guest lecturer at Stanford University and on the Advisory Board of the Stanford Program in Healthcare Innovation.

Read Bio

Steve Leightell is a Principal on the Investment Team at Georgian Partners. He brings 20 years of software experience with operational expertise in channels, partnerships and strategy planning for acquisitions.

Prior to Georgian Partners, Steve led a global team at IBM and was responsible for major systems integrator partnerships. Steve came to IBM via the acquisition of DWL in 2005. At DWL he led the channels and alliances team and played an instrumental role in developing a strategic relationship with IBM that led to the acquisition. Steve’s extensive Sales, Business Development and Corporate Development experience includes roles at AT&T/Allstream, Netcom and PSINet.

Read Bio

Lucian is responsible for the $100M Qualcomm Life Fund (QLF) at Qualcomm Ventures, which focuses on investing in digital healthcare companies. Since Lucian joined Qualcomm Ventures in 2012, he has helped establish QLF as one of the most widely recognized and respected funds in the space, cited as among the most active today by numerous sources including CB Insights, Rock Health, and Startup Health. He is also a general partner at dRx Capital AG, a Novartis and Qualcomm joint investment company. dRx was award best new fund in 2015 by Global Corporate Venturing.

Previously, Lucian worked at McKinsey & Company, where he spent most of his time in the North American healthcare practice advising on clinical and business model transformation for large hospital systems. Prior to that, Lucian was a board certified internal medicine doctor practicing in New York. Lucian trained in internal medicine at Columbia University Medical Center in New York and completed both medical school and his undergraduate studies at Tufts University.